MCID: NRM008
MIFTS: 30

Neuromyelitis Optica Spectrum Disorder

Categories: Rare diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Neuromyelitis Optica Spectrum Disorder

MalaCards integrated aliases for Neuromyelitis Optica Spectrum Disorder:

Name: Neuromyelitis Optica Spectrum Disorder 53
Neuromyelitis Optica 73
Nmosd 53

Classifications:



Summaries for Neuromyelitis Optica Spectrum Disorder

MalaCards based summary : Neuromyelitis Optica Spectrum Disorder, also known as neuromyelitis optica, is related to neuromyelitis optica and multiple sclerosis. An important gene associated with Neuromyelitis Optica Spectrum Disorder is AQP4 (Aquaporin 4). The drugs Mycophenolic acid and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and spinal cord.

Related Diseases for Neuromyelitis Optica Spectrum Disorder

Diseases in the Neuromyelitis Optica family:

Neuromyelitis Optica Spectrum Disorder

Diseases related to Neuromyelitis Optica Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 73)
# Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 11.2
2 multiple sclerosis 10.6
3 myelitis 10.5
4 optic neuritis 10.5
5 neuritis 10.5
6 transverse myelitis 10.4
7 cervicitis 10.2
8 retinitis 10.2
9 depression 10.2
10 myasthenia gravis 10.2
11 sjogren syndrome 10.2
12 encephalitis 10.2
13 cerebritis 10.2
14 myasthenia gravis congenital 10.2
15 lymphoma 10.1
16 lupus erythematosus 10.1
17 anxiety 10.1
18 systemic lupus erythematosus 10.1
19 internuclear ophthalmoplegia 10.1
20 restless legs syndrome 9.9
21 spondylosis 9.9
22 influenza 9.9
23 methotrexate-associated lymphoproliferative disorders 9.9
24 aphasia 9.9
25 lung disease 9.9
26 aging 9.9
27 bronchiolitis 9.9
28 apraxia 9.9
29 adenocarcinoma 9.9
30 autoimmune disease 1 9.9
31 postural orthostatic tachycardia syndrome 9.9
32 interstitial lung disease 9.9
33 arachnoid cysts 9.9
34 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.9
35 dermatomyositis 9.9
36 carcinoid syndrome 9.9
37 lung cancer susceptibility 3 9.9
38 parotitis 9.9
39 purpura 9.9
40 chronic hiccups 9.9
41 autoimmune lymphoproliferative syndrome, type v 9.9
42 meningoencephalitis 9.9
43 autoimmune disease 9.9
44 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.9
45 leukodystrophy 9.9
46 neurosyphilis 9.9
47 b-cell lymphomas 9.9
48 acute cervicitis 9.9
49 myopathy 9.9
50 supranuclear ocular palsy 9.9

Graphical network of the top 20 diseases related to Neuromyelitis Optica Spectrum Disorder:



Diseases related to Neuromyelitis Optica Spectrum Disorder

Symptoms & Phenotypes for Neuromyelitis Optica Spectrum Disorder

Drugs & Therapeutics for Neuromyelitis Optica Spectrum Disorder

Drugs for Neuromyelitis Optica Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 82)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mycophenolic acid Approved Phase 4 24280-93-1 446541
2
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
3
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5 Analgesics Phase 4
6 glucocorticoids Phase 4,Phase 3,Phase 1
7 Topoisomerase Inhibitors Phase 4
8 Hormone Antagonists Phase 4,Phase 3,Phase 1
9 Hormones Phase 4,Phase 3,Phase 1
10 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1
11 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
12 Anti-Bacterial Agents Phase 4
13 Antibiotics, Antitubercular Phase 4
14 Anti-Infective Agents Phase 4
15 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
16 Antitubercular Agents Phase 4
17 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1
18
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
19
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
20
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
21
Azathioprine Approved Phase 2, Phase 3,Phase 3 446-86-6 2265
22 Prednisolone acetate Phase 3,Phase 1,Phase 2
23 Methylprednisolone acetate Phase 3,Phase 1,Phase 2
24 Methylprednisolone Hemisuccinate Phase 3,Phase 1,Phase 2
25 Gastrointestinal Agents Phase 3,Phase 1
26 Neuroprotective Agents Phase 3,Phase 1
27 Prednisolone hemisuccinate Phase 3,Phase 1,Phase 2
28 Prednisolone phosphate Phase 3,Phase 1,Phase 2
29 Antiemetics Phase 3,Phase 1
30 Protective Agents Phase 3,Phase 1
31 Autonomic Agents Phase 3,Phase 1
32 Rho(D) Immune Globulin Phase 3,Phase 2
33 gamma-Globulins Phase 3,Phase 2
34 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
35 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
36 Immunoglobulins, Intravenous Phase 3,Phase 2
37 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
38 Antirheumatic Agents Phase 2, Phase 3,Phase 3,Phase 1
39 Antimetabolites Phase 2, Phase 3,Phase 3
40 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3
41 Immunoglobulin G Phase 3
42 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
43
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
44
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
45
Cetirizine Approved Phase 1, Phase 2 83881-51-0 2678
46
4-Aminopyridine Approved Phase 2 504-24-5 1727
47
Histamine Approved, Investigational Phase 1, Phase 2 75614-87-8, 51-45-6 774
48
Mesna Approved, Investigational Phase 1, Phase 2,Phase 2 3375-50-6 598
49
Cyclophosphamide Approved, Investigational Phase 1, Phase 2,Phase 2 50-18-0, 6055-19-2 2907
50
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860

Interventional clinical trials:

(show all 47)
# Name Status NCT ID Phase Drugs
1 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
2 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
3 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
6 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
7 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
8 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02200770 Phase 2, Phase 3
9 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
10 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Active, not recruiting NCT01892345 Phase 3 Eculizumab
11 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 satralizumab (SA237);Placebo
12 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Enrolling by invitation NCT02003144 Phase 3
13 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
14 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
15 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
16 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
17 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
18 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
19 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
20 Hematopoietic Stem Cell Transplant in Devic's Disease Recruiting NCT00787722 Phase 1, Phase 2
21 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Active, not recruiting NCT02893111 Phase 2 Bortezomib
22 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Active, not recruiting NCT03062579 Phase 1, Phase 2 Tocilizumab
23 Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Terminated NCT01339455 Phase 1, Phase 2
24 Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Unknown status NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
25 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
26 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed NCT01777412 Phase 1 Bevacizumab
27 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
28 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Recruiting NCT02283671 Phase 1
29 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
30 Central Pain Study for ABX-1431 Active, not recruiting NCT03138421 Phase 1 ABX-1431 HCl;Placebo
31 Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Unknown status NCT01024985
32 Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Completed NCT03122873
33 Pathologic-MRI Findings in Atypical IIDD Completed NCT03121105
34 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02836327
35 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
36 Scrambler Trial for Pain in NMOSD Recruiting NCT03452176 Not Applicable
37 The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Recruiting NCT01623076
38 The French Multiple Sclerosis Registry Recruiting NCT02889965
39 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Recruiting NCT02886377
40 Optical Coherence Tomography and Optic Neuritis (OCTON) Recruiting NCT02573792
41 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Recruiting NCT02789670
42 Stem Cell Ophthalmology Treatment Study II Recruiting NCT03011541 Not Applicable
43 Maintenance Plasma Exchange for Neuromyelitis Optica Active, not recruiting NCT01500681
44 Biobank For MS And Other Demyelinating Diseases Active, not recruiting NCT00445367
45 Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China Enrolling by invitation NCT03514030
46 Stem Cell Ophthalmology Treatment Study Enrolling by invitation NCT01920867 Not Applicable
47 Optic Neuritis Differential Diagnosis Study Not yet recruiting NCT03370965 Not Applicable

Search NIH Clinical Center for Neuromyelitis Optica Spectrum Disorder

Genetic Tests for Neuromyelitis Optica Spectrum Disorder

Anatomical Context for Neuromyelitis Optica Spectrum Disorder

MalaCards organs/tissues related to Neuromyelitis Optica Spectrum Disorder:

41
Brain, B Cells, Spinal Cord, Eye, Hypothalamus, Lung, Cortex

Publications for Neuromyelitis Optica Spectrum Disorder

Articles related to Neuromyelitis Optica Spectrum Disorder:

(show top 50) (show all 283)
# Title Authors Year
1
A Case of Transient Pulmonary Interstitial Lesions in Aquaporin-4-positive Neuromyelitis Optica Spectrum Disorder. ( 29780127 )
2018
2
Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder. ( 29519720 )
2018
3
Eye movement abnormalities in AQP4-IgG positive neuromyelitis optica spectrum disorder. ( 29249386 )
2018
4
Comparison of myelin oligodendrocyte glycoprotein (MOG)-antibody disease and AQP4-IgG-positive neuromyelitis optica spectrum disorder (NMOSD) when they co-exist with anti-NMDA (N-methyl-D-aspartate) receptor encephalitis. ( 29414288 )
2018
5
Neuromyelitis optica spectrum disorder presenting as rhomboencephalitis. ( 29794010 )
2018
6
Short-segment transverse myelitis lesions in a cohort of Latin American patients with neuromyelitis optica spectrum disorders. ( 29789706 )
2018
7
Neuromyelitis optica spectrum disorder mimicking extensive leukodystrophy. ( 29676204 )
2018
8
Beneficial effect of plasma exchange in acute attack of neuromyelitis optica spectrum disorders. ( 29414283 )
2018
9
Spectrum of MRI brain lesion patterns in neuromyelitis optica spectrum disorder: a pictorial review. ( 29388807 )
2018
10
Ovarian Reserve in Women With Neuromyelitis Optica Spectrum Disorder. ( 29973905 )
2018
11
Structural and visual functional deficits in a rat model of neuromyelitis optica spectrum disorders related optic neuritis. ( 29913164 )
2018
12
Cerebrospinal fluid mitochondrial DNA in neuromyelitis optica spectrum disorder. ( 29703264 )
2018
13
B cell depleting therapy for multiple sclerosis overlapping with neuromyelitis optica spectrum disorder. ( 29621743 )
2018
14
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? ( 29159373 )
2018
15
Short-term effect of additional apheresis on visual acuity changes in patients with steroid-resistant optic neuritis in neuromyelitis optica spectrum disorders. ( 29802557 )
2018
16
The IL-10-producing regulatory B cells (B10 cells) and regulatory T cell subsets in neuromyelitis optica spectrum disorder. ( 29349658 )
2018
17
Epidemiology of neuromyelitis optica spectrum disorder. ( 29732539 )
2018
18
A Rare Presentation of Neuromyelitis Optica Spectrum Disorders. ( 29434480 )
2018
19
Immunoadsorption plasmapheresis treatment for the recurrent exacerbation of neuromyelitis optica spectrum disorder with a fluctuating anti-aquaporin-4 antibody level. ( 29675599 )
2018
20
Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients. ( 29367170 )
2018
21
Mutation of the cellular adhesion molecule NECL2 is associated with neuromyelitis optica spectrum disorder. ( 29627007 )
2018
22
Short transverse myelitis in Chinese patients with neuromyelitis optica spectrum disorders. ( 29499441 )
2018
23
Association of Visual Impairment in Neuromyelitis Optica Spectrum Disorder With Visual Network Reorganization. ( 29297041 )
2018
24
Time to separate MOG-Ab-associated disease from AQP4-Ab-positive neuromyelitis optica spectrum disorder. ( 29695599 )
2018
25
Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets? ( 29073350 )
2018
26
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms? ( 29159372 )
2018
27
Neuromyelitis Optica Spectrum Disorder Presenting with Pseudoathetosis. ( 29629549 )
2018
28
Incidence of neuromyelitis optica spectrum disorder in the Central Denmark Region. ( 29359475 )
2018
29
MOG-IgG-Associated Optic Neuritis, Encephalitis, and Myelitis: Lessons Learned From Neuromyelitis Optica Spectrum Disorder. ( 29670575 )
2018
30
Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment. ( 29929977 )
2018
31
Vaccines and the association with relapses in patients with neuromyelitis optica spectrum disorder. ( 29783157 )
2018
32
MRI Features of Aquaporin-4 Antibody-Positive Longitudinally Extensive Transverse Myelitis: Insights into the Diagnosis of Neuromyelitis Optica Spectrum Disorders. ( 29449281 )
2018
33
Worldwide prevalence of neuromyelitis optica spectrum disorders. ( 29436488 )
2018
34
Validation of the Modified Fatigue Impact Scale and the relationships among fatigue, pain and serum interleukin-6 levels in patients with neuromyelitis optica spectrum disorder. ( 29406915 )
2018
35
Comparison of efficacy and tolerability of azathioprine, mycophenolate mofetil, and lower dosages of rituximab among patients with neuromyelitis optica spectrum disorder. ( 29406904 )
2018
36
Only Follow-Up of Memory B Cells Helps Monitor Rituximab Administration to Patients with Neuromyelitis Optica Spectrum Disorders. ( 29881979 )
2018
37
Development of Neuromyelitis Optica Spectrum Disorder and Spinal Arachnoid Cysts in a Patient With Intractable Epilepsy. ( 29379967 )
2018
38
Bortezomib for Neuromyelitis Optica Spectrum Disorder: A New Therapeutic Option for the More Severe Forms?-Reply. ( 29159366 )
2018
39
Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report. ( 29361915 )
2018
40
Rituximab-induced interstitial lung disease in a patient with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder. ( 29414297 )
2018
41
Study of the placentae of patients with neuromyelitis optica spectrum disorder. ( 29571847 )
2018
42
Use of Rituximab and Risk of Re-hospitalization for Children with Neuromyelitis Optica Spectrum Disorder. ( 29782625 )
2018
43
Comparative study of quality of life, anxiety, depression, and fatigue among patients with neuromyelitis optica spectrum disorder and multiple sclerosis: The first report from Iran. ( 29775851 )
2018
44
A protean disease: The phenotypic range of neuromyelitis optica spectrum disorder. ( 28814129 )
2017
45
Screening for onconeural antibodies in neuromyelitis optica spectrum disorders. ( 28068933 )
2017
46
Syndrome of inappropriate antidiuretic hormone secretion associated with seronegative neuromyelitis optica spectrum disorder. ( 28393003 )
2017
47
Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder. ( 28946890 )
2017
48
Pregnancy in neuromyelitis optica spectrum disorder: A multicenter study from South China. ( 28017203 )
2017
49
Treatment-resistant neuromyelitis optica spectrum disorders associated with Toxocara canis infection: A case report. ( 28427692 )
2017
50
Effectiveness and safety of immunosuppressive therapy in neuromyelitis optica spectrum disorder during pregnancy. ( 28477712 )
2017

Variations for Neuromyelitis Optica Spectrum Disorder

Expression for Neuromyelitis Optica Spectrum Disorder

Search GEO for disease gene expression data for Neuromyelitis Optica Spectrum Disorder.

Pathways for Neuromyelitis Optica Spectrum Disorder

GO Terms for Neuromyelitis Optica Spectrum Disorder

Sources for Neuromyelitis Optica Spectrum Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....